ArticleAPL bioengineering2017
An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements.
Article in APL bioengineering, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- First Human Trial of High-Frequency Irreversible Electroporation Therapy for Prostate Cancer.Technology in cancer research & treatment · 2018Trial
- Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom.BJUI compass · 2025Review
- Advances in irreversible electroporation for prostate cancer.Discover oncology · 2024Review
- Burst sine wave electroporation (B-SWE) for expansive blood-brain barrier disruption and controlled non-thermal tissue ablation for neurological disease.APL bioengineering · 2024Article
- Pulsed Field Ablation for Atrial Fibrillation: Mechanisms, Advantages, and Limitations.Reviews in cardiovascular medicine · 2024Review
- Liver-tumor mimics as a potential translational framework for planning and testing irreversible electroporation with multiple electrodes.Bioengineering & translational medicine · 2024Article
- Determination of lethal electric field threshold for pulsed field ablation inFrontiers in cardiovascular medicine · 2023Article
- Effects of different applied voltages of irreversible electroporation on prostate cancer in a mouse model.Scientific reports · 2022Article
- A Comparative Modeling Study of Thermal Mitigation Strategies in Irreversible Electroporation Treatments.Journal of heat transfer · 2022Article
- Electromagnetically Stimuli-Responsive Nanoparticles-Based Systems for Biomedical Applications: Recent Advances and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2021Review
- Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences.Therapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irreversible electroporation (IRE) is an emerging cancer treatment that utilizes non-thermal electric pulses for tumor ablation. The pulses are delivered through minimally invasive needle electrodes inserted into the target tissue and lead to cell death through the creation of nanoscale membrane defects. IRE has been shown to be safe and effective when performed on tumors in the brain, liver, kidneys, pancreas, and prostate that are located near critical blood vessels and nerves. Accurate treatment planning and prediction of the ablation volume require
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.